快樂小藥師
本部落格為介紹醫藥相關知識部落格,並沒有販賣藥品。此外文章部分內容可能會引起您的不安或是心理不適,在按下繼續閱讀前,請先自我評估,謝謝(原創文章如需轉載請先告知 左右水平廣告輪播-語法
  • // 如果你希望圖片繼續多一點,那就自己再複製增加

目前分類:MedScape (164)

瀏覽方式: 標題列表 簡短摘要

tedizolid  

A new antibiotic, tedizolid phosphate, appears to be a reasonable alternative to linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI): A short (6-day) course of tedizolid phosphate was as effective as a 10-day course of linezolid with regard to both early and sustained clinical responses.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

IMG_6944   

Question

What is the significance of reports of adverse cardiac outcomes associated with calcium supplements?

Response from Darrell Hulisz, PharmD 

Associate Professor, Case Western Reserve University School of Medicine; Clinical Specialist in Family Medicine, University Hospitals, Case Medical Center, Cleveland, Ohio

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

fig1  

Lars Grimm, MD, MHS Contributor Information

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

Tecfidera Product Shot  

The US Food and Drug Administration (FDA) has approved dimethyl fumarate (Tecfidera, Biogen Idec) for the treatment of relapsing-remitting multiple sclerosis (MS).

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

Sensipar30

Sensipar 60 mg

Sensipar90  

The US Food and Drug Administration (FDA) today announced that it has halted all pediatric clinical trials of cinacalcet (Sensipar, Amgen), a calcium-lowering drug, after the recent death of a 14-year-old patient in a study.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

hospitalreadmit1216-600x399  

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

TAK06100

omontys  

The anemia drug peginesatide (Omontys, Affymax and Takeda Pharmaceuticals) has been voluntarily recalled by the manufacturers after reports of anaphylaxis leading to 3 deaths, the US Food and Drug Administration (FDA) announced today.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

4-image  

The US Food and Drug Administration (FDA) has expanded the approved use of deferasirox (Exjade, Novartis) to treat patients aged 10 years and older with chronic iron overload due to nontransfusion-dependent thalassemia (NTDT), the agency announced today.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

asthma2  

Abstract and Introduction

Abstract

Current therapy for asthma with inhaled corticosteroids and long-acting inhaled β2-agonists is highly effective, safe, and relatively inexpensive, but many patients remain poorly controlled. Most advances have been through improving these drug classes and a major developmental hurdle is to improve existing drug classes. Major unmet needs include better treatment of severe asthma (which has some similarity to chronic obstructive pulmonary disease), as well as curative therapies for mild to moderate asthma that do not result in the return of symptoms when the treatment is stopped. Several new treatments are in development, but many are specific, targeting a single mediator or receptor, and are unlikely to have a major clinical impact, although they may be effective in specific asthma phenotypes (endotypes). Drugs with more widespread effects, such as kinase inhibitors, may be more effective but have a greater risk of side effects so inhaled delivery may be needed. Several new treatments target the underlying allergic/immune process and would treat concomitant allergic diseases. Improved immunotherapy approaches have the potential for disease modification, although prospects for a cure are currently remote.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

fosfomycin 2 g  

Question

Can fosfomycin treat multidrug-resistant urinary tract infections?

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

voltaren-24814_1  

LONDON — The European Medicines Agency (EMA) has finalized a review of recently published information on the cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs) and concludes that the latest evidence shows a consistent but small increase in the risk of cardiovascular side effects with diclofenac compared with other NSAIDs [1]. The risk with diclofenac is "similar to the risks of COX-2 inhibitors," it states.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

alzheimcleavagenat  

Investigators have selected the first drugs to be evaluated in an Alzheimer's disease (AD) prevention trial.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

Doxycycline 100 mg Cap-VER  

Does Doxycycline Protect Against Development of Clostridium difficile Infection?

Doernberg SB, Winston LG, Deck DH, Chambers HF
Clin Infect Dis. 2012;55:615-620.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

螢幕快照 2012-10-07 上午12.53.06  

A new position statement for the treatment of type 2 diabetes takes an approach much more focused on the individual patient compared with the "one number fits all" target of glycated hemoglobin (HbA1c) used up to now.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

001  

學名藥或原廠藥?處方者的經驗談.......

參考看看吧

Brand-Name vs Generic Agents: The Prescriber Experience

Prescribers and patients often voice concerns about the safety and efficacy of generic drugs that are substituted for brand-name drug products. Love 'em or hate 'em, they are with us to stay. The US Food and Drug Administration (FDA) approves a generic substitute if it has proven to be "identical, or bioequivalent, to a brand-name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use."[1]

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

small__268846488  

Question:

What are the maximum doses of potassium, calcium, phosphorus, and magnesium that can be taken orally without significant adverse effect and with maximum clinical effect?

口服鉀、鈣、磷、鎂的建議最大有效劑量(沒有明顯副作用)是多少呢?

Response from Jenny A. Van Amburgh, PharmD, CDE 
Assistant Dean of Academic Affairs and Associate Clinical Professor, School of Pharmacy, Northeastern University; Director, Clinical Pharmacy Team and Residency Program Director, Harbor Health Services, Inc., Boston, Massachusetts

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

NSTEMI  

CLINICAL CONTEXT

According to the current study by Jneid and colleagues, new evidence is available on the management of unstable angina. This report replaces the 2007 American College of Cardiology Foundation/American Heart Association (ACC/AHA) Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (UA/NSTEMI) that were updated by the 2011 guidelines.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

eliquis_2.5mg  

An indirect comparison of the new oral anticoagulant drugs, with all the caveats that such comparisons entail, suggests there is no profound difference between apixaban (Eliquis, Pfizer/Bristol-Myers Squibb), rivaroxaban (Xarelto, Bayer/Johnson & Johnson), or dabigatran (Pradaxa, Boehringer Ingelheim) in terms of efficacy [1]. The higher dose of dabigatran, 150 mg, was superior to rivaroxaban in terms of lowering the risk of stroke or systemic embolism, while the risk of major bleeding was significantly lower with dabigatran 110 mg or apixaban when compared with rivaroxaban.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

2012051111464968  

CLINICAL CONTEXT

Lorcaserin is a serotonin 2C receptor agonist indicated for chronic weight management in adults when used in conjunction with a caloric restriction diet and increased physical activity. The effect of lorcaserin on cardiovascular morbidity and mortality has not been established.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

INTRODUCTION

There is increasing recognition of the similarities in the etiology of constipation predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC), and a more inclusive terminology is emerging of constipation-related functional gastrointestinal (GI) disorders, which embraces both conditions. This is partly driven by the increasing appreciation that IBS-C and CC share a number of common underlying causes and presenting symptoms, which are described below.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()

您尚未登入,將以訪客身份留言。亦可以上方服務帳號登入留言

請輸入暱稱 ( 最多顯示 6 個中文字元 )

請輸入標題 ( 最多顯示 9 個中文字元 )

請輸入內容 ( 最多 140 個中文字元 )

請輸入左方認證碼:

看不懂,換張圖

請輸入驗證碼